The text starts here.

News Release

FOR IMMEDIATE RELEASE
October 19, 2006
For Print (PDF 113KB)

Sanko Junyaku, Eisai, and FUJIREBIO Sign Joint Research Agreement for Development of a New KL-6 Test Kit (supplementary diagnostic marker for interstitial pneumonia) compatible with LUMIPULSE(R) (automatic chemiluminescent enzyme immunoassay system)

Sanko Junyaku Co., Ltd.
Eisai Co., Ltd.
FUJIREBIO INC.

Sanko Junyaku Co., Ltd. (Headquarters: Tokyo, President: Masao Jinbo), Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito), and FUJIREBIO INC. (Headquarters: Tokyo, President: Hiromasa Suzuki) announced today that the three companies concluded on October 19, 2006 a joint research agreement for development of a new KL-6 test kit consists of an in-vitro, supplementary diagnostic marker for interstitial pneumonia compatible with the LUMIPULSE(R) (an automatic chemiluminescent enzyme immunoassay system) systems.

Currently Sanko Junyaku manufactures and markets under the sales agreement with Eisai two test kits for interstitial pneumonia, EITEST(R) KL-6 (sandwich enzyme immunoassay method) and PICOLUMI(R) KL-6 (electrochemiluminescence immunoassay) for measurement of KL-6, a serum marker that is highly distinctive for the diagnosis of this disease. With this agreement, the three companies will aim to develop a new KL-6 test kit compatible with diagnosis by the LUMIPULSE(R) systems, allowing for greater ease of use in diagnosis of interstitial pneumonia.

FUJIREBIO markets three automatic chemiluminescent enzyme immunoassay systems, LUMIPULSE(R)f, LUMIPULSE(R) S, and LUMIPULSE (R) Presto II. Today, more than 1000 LUMIPULSE(R) systems have been used in medical institutions throughout Japan. The development of a new KL-6 test kit will further extend the measurement items of the LUMIPULSE(R) systems, giving them the higher diagnostic capability.

According to the joint agreement announced today, the new KL-6 test kit will be manufactured by FUJIREBIO. In addition, Sanko Junyaku together with its alliance partner Eisai will be responsible for marketing and sales of the products.

Typical types of interstitial pneumonia include cryptogenic interstitial pneumonia and drug-induced pneumonia, both of which are designated intractable disorders. Furthermore, cases of drug-induced pneumonia have been increasing recently which raises the significance and public concern around this disease. Sanko Junyaku, Eisai, and FUJIREBIO are committed to increasing the benefits to patients and their families by development of this new test kit for interstitial pneumonia made possible by this joint agreement.


[Please refer to the following note for the glossary and corporate profiles]


[Contacts:]

Sanko Junyaku Co., Ltd. Eisai Co., Ltd.FUJIREBIO INC.
IR Department
Attn: Nishina
Corporate
Communications Department
Corporate Planning
Department
Tel: +81-(0)3-3865-4311Tel: +81-(0)3-3817-5120Tel: +81-(0)3-5695-9207

[Glossary]
  • Automatic Chemiluminescent Enzyme Immunoassay System

  • An automated test system by CLEIA (chemiluminescent enzyme immunoassay) using chemiluminescence substrate. Minute substances in vivo are detected and measured by chemiluminescence method using enzyme.

  • Interstitial pneumonia

  • Lungs are shaped like a bunch of grapes which consist of multiple alveoli, small tissues which intake oxygen. Pneumonia is caused by inflammation in the alveolus and can be classified into two groups depending on where the inflammation occurs: interstitial pneumonia, which occurs in the walls of the alveoli (interstitium), and alveolar pneumonia (generally known as pneumonia), which occurs inflammation in the air duct between bronchi and alveoli. Differential diagnosis is required since treatment methods for these two kinds of pneumonia are different.

  • KL-6 (sialogycoprotein antigen)

  • KL-6 is found on type II alveolar epithelial cells which consist of the walls of the alveolus (interstitium). In interstitial pneumonia, such type II alveolar epithelial cells are excessively formed and the KL-6 level increases. Thus, measurement of the KL-6 level is effective for the diagnosis of interstitial pneumonia since KL-6 extravasate into cells.



Corporate Profiles
Sanko Junyaku Co., Ltd.
Representative Masao Jimbo
Location of headquarters 1-10-6 Iwamoto-cho, Chiyoda-ku, Tokyo, Japan
Operations Manufacturing, marketing and import of in vitro diagnostics, laboratory reagents, laboratory instruments, etc.
Capital 5,262 million yen (50.59% owned by Eisai, as of March 31, 2006)

Eisai Co., Ltd.
Representative Haruo Naito
Location of headquarters 4-6-10 Koishikawa, Bunkyo-ku, Tokyo, Japan
Operations Research & development, manufacturing, marketing and export of pharmaceuticals.
Capital 44,985 million yen (as of March 31, 2006)

FUJIREBIO INC.
Representative Hiromasa Suzuki
Location of headquarters 2-62-5 Nihonbashi-hamacho, Chuo-ku, Tokyo, Japan
Operations Manufacturing, marketing, and import/export of in vitro diagnostics, laboratory equipments and other supplies.
Capital 2,000 million yen (as of March 31, 2006)